Original Research
Original Research
Intravenous Ketamine for Treatment-Resistant Depression
September 12, 2022
The clinical effectiveness of ketamine for suicidal ideation and treatment-resistant depression outside of controlled clinical trials is unclear. This article reports clinical outcomes of a large cohort treated with...
Original Research
Young Adult Depression, Antidepressant Prescriptions, and Therapy Intensification in the US
September 6, 2022
This study evaluated the temporal trend in young adult depression, prescription patterns of first- and second-line antidepressants, and factors influencing therapy intensification for depression stratified by sex.
Original Research
Impact of SUD on COVID-19 Outcomes
August 29, 2022
Identifying risk factors that predispose individuals to negative COVID-19 outcomes is important. The current study examined the association between substance use disorders, psychiatric diagnosis, and COVID-19–related clinical outcomes.
Original Research
Add-on Pramipexole for Schizophrenia
August 1, 2022
Several small clinical trials have reported that the dopamine agonist pramipexole was beneficial in treating patients with schizophrenia. This 16-week, multicenter, double-blind, randomized, placebo-controlled study was conducted to test...
Original Research
Amphetamine Extended-Release Tablets for Adult ADHD
July 20, 2022
Treating attention-deficit/hyperactivity disorder (ADHD) in adults can improve long-term outcomes, such as reducing suicidal behavior and mortality. This study evaluated the efficacy and safety of amphetamine extended-release tablets in...